Urology & Nephrology-Focused Preclinical CRO

KCI Biotech is a preclinical CRO urology and nephrology CRO provider. We deliver reproducible, GLP-compliant in vivo efficacy studies to accelerate renal drug discovery and clinical translation.

Why Use Animal Models in Urological Research

Because complex mechanisms like renal fibrosis and tubular necrosis cannot be modeled in vitro, animal models of kidney disease are indispensable. Partnering with an experienced renal CRO provides the objective physiological readouts and controlled conditions required to validate novel therapies.

Our Portfolio of Urinary System Disease Models 

KCI Biotech provides validated in vivo systems for acute, chronic, and secondary renal diseases:

Acute Kidney Injury (AKI) Models

• Ischemia-reperfusion-induced AKI model in rodents, rabbits, and dogs
• Cisplatin-induced and glycerol-induced acute renal failure models

Chronic Kidney Disease (CKD) & Fibrosis

• 5/6 nephrectomy CKD model and adenine-induced uremia model
• Unilateral ureteral obstruction (UUO) and adriamycin-induced kidney disease models

Secondary Nephropathy & Urological Conditions 

• CKD mouse model and rat variants for diabetic (STZ) and hypertensive (DOCA-salt) nephropathy
• Immune-mediated models (IgA nephropathy, passive Heymann nephritis) and cyclophosphamide-induced cystitis

Comprehensive Urology CRO Solutions & Collaboration

KCI Biotech delivers integrated preclinical solutions to de-risk renal drug candidates:

Portfolio: a variety of specific urological models within a library of 500+ validated disease models.

Facilities & Species: 18,000 m² AAALAC-accredited facilities supporting mice, rats, rabbits, dogs, and non-human primates.

Evaluation Platforms: Clinical pathology (creatinine, BUN), urinalysis, and histopathology (fibrosis scoring).

Track Record: Supporting 200+ IND filings (NMPA/FDA) for 1000+ global pharmaceutical clients.

From nephroprotection to anti-fibrotic evaluation, we provide tailored preclinical study designs. Contact our team today.